| Literature DB >> 24456585 |
Chun-Ta Huang, Yi-Ju Tsai, Jou-Wei Lin, Sheng-Yuan Ruan, Huey-Dong Wu, Chong-Jen Yu.
Abstract
INTRODUCTION: The process of weaning may impose cardiopulmonary stress on ventilated patients. Heart-rate variability (HRV), a noninvasive tool to characterize autonomic function and cardiorespiratory interaction, may be a promising modality to assess patient capability during the weaning process. We aimed to evaluate the association between HRV change and weaning outcomes in critically ill patients.Entities:
Mesh:
Year: 2014 PMID: 24456585 PMCID: PMC4056081 DOI: 10.1186/cc13705
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1A flow diagram of the study patients and their outcomes. SBT, spontaneous breathing trial.
Baseline features of the study population according to the outcome of SBT
| Age, years | 65 ± 18 | 71 ± 16 | 0.186 |
| ≧65 years | 45 (58) | 17 (71) | 0.276 |
| Male sex | 54 (70) | 12 (50) | 0.070 |
| Body mass index | 22 ± 4 | 23 ± 4 | 0.378 |
| APACHE II | 17 ± 6 | 16 ± 7 | 0.767 |
| Comorbidities | | | |
| Cerebrovascular disease | 16 (21) | 4 (17) | 0.776 |
| COPD | 19 (25) | 7 (29) | 0.660 |
| Heart failure | 3 (4) | 1 (4) | 0.999 |
| Liver cirrhosis | 4 (5) | 1 (4) | 0.999 |
| End-stage renal disease | 6 (8) | 2 (8) | 0.999 |
| Diabetes mellitus | 26 (34) | 6 (25) | 0.420 |
| Hypertension | 30 (39) | 8 (33) | 0.619 |
| Coronary artery disease | 5 (7) | 3 (13) | 0.391 |
| Cause of acute respiratory failure | | | |
| Pneumonia | 34 (44) | 15 (63) | 0.116 |
| Sepsis | 15 (20) | 3 (13) | 0.551 |
| Acute exacerbation of COPD | 3 (4) | 1 (4) | 0.999 |
| Gastrointestinal bleeding | 10 (13) | 1 (4) | 0.452 |
| Lung edema | 4 (5) | 1 (4) | 0.999 |
| Neurologic disease | 6 (8) | 3 (13) | 0.440 |
| Others | 5 (7) | 0 (0) | 0.335 |
| Time to first SBT, hours | 96 ± 103 | 94 ± 71 | 0.931 |
| Medications | | | |
| β2 agonist | 28 (36) | 17 (71) | 0.003 |
| Anticholinergic | 22 (29) | 16 (67) | 0.001 |
| ACEI/ARB | 8 (10) | 2 (8) | 0.999 |
| CCB | 27 (35) | 13 (54) | 0.095 |
| β blocker | 11 (14) | 3 (13) | 0.999 |
Data are presented as mean ± standard deviation or number (%).
ACEI, angiotensin-converting-enzyme inhibitor; APACHE, acute physiology and chronic health evaluation; ARB, angiotensin-receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; SBT, spontaneous breathing trial.
Weaning parameters, oxygenation status, and ventilator modes before SBT based on the outcome of SBT
| Weaning parameters | | | |
| Respiratory rate <30 per minute | 70 (91) | 21 (88) | 0.698 |
| Minute ventilation ≦10 L/minute | 63 (82) | 19 (79) | 0.770 |
| Tidal volume ≧5 ml/kg | 57 (74) | 15 (63) | 0.276 |
| RSBI <105/min/L | 71 (92) | 21 (88) | 0.440 |
| PImax ≦20 cmH2O | 73 (95) | 24 (100) | 0.570 |
| PaO2/FIO2 | 318 ± 112 | 279 ± 101 | 0.128 |
| Pre-SBT ventilator settings | | | |
| PSV | 73 (95) | 21 (88) | 0.674 |
| PCV | 2 (3) | 1 (4) | |
| SIMV | 1 (1) | 1 (4) | |
| VCV | 1 (1) | 1 (4) |
Data are presented as mean ± standard deviation or number (%).
FIO2, fraction of inspired oxygen; PaO2, partial pressure of oxygen in arterial blood; PCV, pressure-controlled ventilation; PImax, maximal inspiratory pressure; PSV, pressure-support ventilation; RSBI, rapid shallow-breathing index; SBT, spontaneous breathing trial; SIMV, synchronized intermittent mandatory ventilation; VCV, volume-controlled ventilation.
Measurement of heart-rate variability during pre-SBT and SBT periods
| VLF [ln(ms2)] | | | | |
| Successful SBT | 6.9 (1.3) | 6.3 (1.6) | 0.220 | |
| Failed SBT | 6.6 (1.1) | 5.5 (1.5) | | |
| LF% (nu) | | | | |
| Successful SBT | 38 (20) | 40 (23) | 0.687 | |
| Failed SBT | 38 (20) | 38 (20) | | |
| HF% (nu) | | | | |
| Successful SBT | 45 (15) | 44 (18) | 0.775 | |
| Failed SBT | 47 (14) | 45 (16) | | |
| TP [ln(ms2)] | | | | |
| Successful SBT | 7.9 (1.0) | 7.7 (1.0) | 0.036 | 0.092 |
| Failed SBT | 8.2 (0.7) | 7.4 (0.9) | | 0.003 |
| LF/HF [ln(ratio)] | | | | |
| Successful SBT | 1.0 (0.2) | 1.0 (0.3) | 0.597 | |
| Failed SBT | 1.0 (0.1) | 1.0 (0.2) |
aFor comparison between successful and failed spontaneous-breathing trial groups.
bFor comparison between pre-spontaneous-breathing trial and spontaneous-breathing trial periods within a group.
Data are presented as mean (standard deviation).
SBT, spontaneous breathing trial; VLF, very low frequency; HF, high frequency; LF, low frequency; ln, natural logarithm; nu, normalized unit; TP, total power.
Figure 2Effect of spontaneous-breathing trial (SBT) and extubation on heart-rate variability. (A) Patients who failed SBT had a significant decrease in total power (TP) at the change from pre-SBT to SBT periods. (B) Patients with successful extubation had a significant increase in TP from SBT to postextubation periods. Values are presented in means. Asterisks indicate significant changes. ln, natural logarithm.
Multivariate logistic regression model for development of SBT failure
| Age ≧65 years | 1.1 (0.3-3.6) | 0.917 |
| Female sex | 3.0 (1.0-9.4) | 0.054 |
| Use of β2 agonist | 4.0 (0.9-18.3) | 0.075 |
| Use of anticholinergic | 2.9 (0.6-13.0) | 0.163 |
| Use of CCB | 2.3 (0.7-6.8) | 0.149 |
| Δln TP ≤0.4 ln(ms2) | 7.2 (2.0-25.4) | 0.002 |
CCB, calcium channel blocker; CI, confidence interval; Δln TP, change of natural logarithmic transformation of total power from pre-SBT to SBT periods; SBT, spontaneous-breathing trial.
Features of extubated patients according to the outcome of extubation
| Age, years | 64 ± 19 | 71 ± 15 | 0.247 |
| ≧65 years | 36 (56) | 9 (69) | 0.387 |
| Male sex | 45 (70) | 9 (70) | 0.999 |
| Body mass index | 22 ± 5 | 21 ± 3 | 0.373 |
| APACHE II | 17 ± 6 | 19 ± 7 | 0.303 |
| Comorbidities | | | |
| Cerebrovascular disease | 14 (22) | 2 (15) | 0.725 |
| COPD | 16 (25) | 3 (23) | 0.999 |
| Heart failure | 3 (5) | 0 (0) | 0.999 |
| Liver cirrhosis | 3 (5) | 1 (8) | 0.530 |
| End-stage renal disease | 4 (6) | 2 (15) | 0.266 |
| Diabetes mellitus | 23 (36) | 3 (23) | 0.525 |
| Hypertension | 26 (41) | 4 (31) | 0.506 |
| Coronary artery disease | 5 (8) | 0 (0) | 0.582 |
| Cause of acute respiratory failure | | | |
| Pneumonia | 29 (45) | 5 (39) | 0.650 |
| Sepsis | 13 (20) | 2 (15) | 0.999 |
| Acute exacerbation of COPD | 2 (3) | 1 (8) | 0.430 |
| Gastrointestinal bleeding | 8 (13) | 2 (15) | 0.674 |
| Lung edema | 4 (6) | 0 (0) | 0.999 |
| Neurologic disease | 4 (6) | 2 (15) | 0.266 |
| Others | 4 (6) | 1 (8) | 0.999 |
| Time to first SBT, hours | 102 ± 109 | 64 ± 55 | 0.221 |
| Medications | | | |
| β2 agonist | 22 (34) | 6 (46) | 0.530 |
| Anticholinergic | 17 (27) | 5 (39) | 0.502 |
| ACEI/ARB | 7 (11) | 1 (8) | 0.999 |
| CCB | 24 (38) | 3 (23) | 0.525 |
| β blocker | 9 (14) | 2 (15) | 0.999 |
Data are presented as mean ± standard deviation or number (%).
ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor blocker; APACHE, Acute Physiology And Chronic Health Evaluation; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; SBT, spontaneous breathing trial.
Weaning parameters, oxygenation status, and ventilator modes before SBT based on the outcome of extubation
| Weaning parameters | | | |
| Respiratory rate <30/min | 57 (89) | 13 (100) | 0.595 |
| Minute ventilation ≦10 L/min | 51 (80) | 12 (92) | 0.442 |
| Tidal volume ≧5 ml/kg | 47 (73) | 10 (77) | 0.999 |
| RSBI <105 /min/L | 59 (92) | 12 (92) | 0.999 |
| PImax ≦20 cmH2O | 60 (94) | 13 (100) | 0.999 |
| PaO2/FIO2 | 318 ± 115 | 319 ± 100 | 0.980 |
| Ventilator settings before SBT | | | |
| PSV | 61 (95) | 12 (92) | 0.592 |
| PCV | 1 (2) | 1 (8) | |
| SIMV | 1 (2) | 0 (0) | |
| VCV | 1 (2) | 0 (0) |
Data are presented as mean ± standard deviation or number (%).
FIO2, fraction of inspired oxygen; PaO2, partial pressure of oxygen in arterial blood; PCV pressure-controlled ventilation; PImax, maximal inspiratory pressure; PSV, pressure-support ventilation; RSBI, rapid shallow-breathing index; SBT, spontaneous-breathing trial; SIMV, synchronized intermittent mandatory ventilation; VCV, volume-controlled ventilation.
Measurement of heart-rate variability during SBT and postextubation periods
| VLF (ln(ms2)) | | | | |
| Successful extubation | 6.4 (1.7) | 6.9 (1.2) | 0.015 | 0.003 |
| Extubation failure | 6.1 (1.4) | 5.5 (1.9) | | 0.187 |
| LF% (nu) | | | | |
| Successful extubation | 43 (23) | 43 (19) | 0.783 | |
| Extubation failure | 26 (12) | 27 (18) | | |
| HF% (nu) | | | | |
| Successful extubation | 43 (18) | 44 (15) | 0.956 | |
| Extubation failure | 51 (14) | 52 (15) | | |
| TP (ln(ms2)) | | | | |
| Successful extubation | 7.7 (1.0) | 8.1 (0.8) | 0.025 | 0.004 |
| Extubation failure | 7.5 (1.1) | 7.2 (0.9) | | 0.182 |
| LF/HF (ln(ratio)) | | | | |
| Successful extubation | 1.0 (0.3) | 1.0 (0.2) | 0.954 | |
| Extubation failure | 0.9 (0.1) | 0.9 (0.2) |
aFor comparison between successful extubation and extubation-failure groups.
bFor comparison between spontaneous-breathing trial and postextubation periods within a group.
Data are presented as mean (standard deviation).
HF, high frequency; LF, low frequency; ln, natural logarithm; nu, normalized unit; SBT, spontaneous breathing trial; TP, total power. VLF, very low frequency.